

# Randomised controlled trial investigating needle aspiration versus chest drain for secondary spontaneous pneumothorax

<b>Submission date</b> 17/04/2023	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 09/05/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 15/04/2025	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Secondary spontaneous pneumothorax (SSP) is where an abnormal collection of air develops in the space between the lung and the chest wall causing lung collapse. This type of pneumothorax is called secondary as it happens in patients with pre-existing lung conditions such as emphysema and is called spontaneous as it occurs without injury. Currently, SSP is typically treated by inserting a drain into the chest to remove the air. The drain usually stays in place for a week leading to a long hospital stay. A different procedure, needle aspiration, involves inserting a small plastic tube into the chest and removing the air with a syringe over roughly 20 minutes. This is a simpler procedure which means patients may avoid the need to have a chest drain. A previous small study found that patients spent less time in the hospital, and had fewer complications when treated with a needle aspiration. However, because only a small number of people were included in this study, we cannot be completely sure of the results. The PRINCE-SSP study would like to confirm these findings in a bigger study.

### Who can participate?

Adults who have a symptomatic SSP if the pneumothorax is of sufficient size and symptoms would require intervention with a chest drain

### What does the study involve?

Participants are randomised to receive either needle aspiration or chest drain (usual care). Needle aspiration involves inserting a small needle into the chest and the air is manually aspirated to remove the air. A chest drain involves the insertion of a drain into the chest wall which is stitched in place and attached to a drainage system. A chest drain stays in place for at least 24 hours and requires hospital admission. Needle aspiration takes approximately 20 minutes and is a one-off procedure. Participants will be asked some questions within the first 24 hours after their treatment and will receive a routine chest x-ray before they are discharged. Participants will be asked to complete some questionnaires on days 1 to 5 after their treatment and if they have been discharged home before day 5 they will be given a diary to take home and record some information. Participants will then attend a routine 30-day follow-up appointment where they will be asked some more questions and receive another chest x-ray. A researcher will

also look at relevant sections of participants' medical notes to record details of their care (e.g. how long they stayed in the hospital) and any complications they might have experienced.

What are the possible benefits and risks of participating?

Both treatments have advantages and disadvantages and this research will help determine whether doctors should change their practice for the treatment of SSP. There are no direct benefits from taking part in the trial. Both needle aspiration and chest drain are standard treatments used to treat various types of pneumothorax. If needle aspiration is not successful then a chest drain may need to be inserted after the needle aspiration to drain the air between the lung and chest wall. This could be seen as a delay in having the chest drained and the pneumothorax could worsen with time. Participants will be closely monitored throughout the study. Chest X-rays are performed as part of participants' routine care and participants will not undergo any additional chest X-rays in this trial.

Where is the study run from?

Multiple sites across England and Wales from within emergency departments or acute medical units (UK)

When is the study starting and how long is it expected to run for?

November 2022 to June 2025

Who is funding the study?

National Institute for Health and Care Research (NIHR) Research for Patient Benefit (RfPB) programme (UK)

Who is the main contact?

Dr Steven Walker (Co-PI), [steven.walker@bristol.ac.uk](mailto:steven.walker@bristol.ac.uk) (UK)

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Nick Maskell

### ORCID ID

<https://orcid.org/0000-0002-1276-6500>

### Contact details

Academic Respiratory Unit

L&R Building

University of Bristol

Southmead Hospital

Bristol

United Kingdom

BS10 5NB

None available

[nick.maskell@bristol.ac.uk](mailto:nick.maskell@bristol.ac.uk)

### Type(s)

Public

**Contact name**

Dr Study Team

**Contact details**

-  
-

United Kingdom

-

None available

prince-ssp@exeter.ac.uk

**Type(s)**

Scientific

**Contact name**

Prof Nick Maskell

**Contact details**

Academic Respiratory Unit

L&R Building

University of Bristol

Southmead Hospital

Bristol

United Kingdom

BS10 5NB

None available

nick.maskell@bristol.ac.uk

**Type(s)**

Principal investigator

**Contact name**

Dr Steven Walker

**Contact details**

University of Bristol

Learning and Research Building

Southmead Hospital

Bristol

United Kingdom

BS10 5NB

+44 (0)117 4148114

steven.walker@bristol.ac.uk

**Additional identifiers**

**Clinical Trials Information System (CTIS)**

Nil known

## **Integrated Research Application System (IRAS)**

324020

## **ClinicalTrials.gov (NCT)**

Nil known

## **Protocol serial number**

CPMS 55271, IRAS 324020

# **Study information**

## **Scientific Title**

Pragmatic non-inferiority randomised trial investigating needle aspiration versus chest drain for secondary spontaneous pneumothorax

## **Acronym**

PRINCE-SSP

## **Study objectives**

Is the length of initial hospital stay in spontaneous secondary pneumothorax patients managed with needle aspiration no worse than for secondary spontaneous pneumothorax patients managed with a chest drain (usual care), whilst demonstrating benefits in other important patient-reported, clinical and cost-effectiveness outcomes?

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Approved 27/04/2023, Wales REC 7 (Health and Care Research Wales, Castlebridge 4, Cardiff, CF11 9AB, UK; +44 (0)2922 941107, (0)2922 940954, (0)2922 940968; wales.REC7@wales.nhs.uk), ref: 23/WA/0085

## **Study design**

Multi-centre randomized controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Secondary spontaneous pneumothorax

## **Interventions**

Study design:

- Randomised controlled trial to see if the intervention (needle aspiration, NA) is non-inferior to standard care (intercostal chest drain, ICD) in patients with secondary spontaneous pneumothorax (SSP), with respect to the initial length of hospital stay, patient-reported outcomes, clinical and cost-effectiveness outcomes.

- Emergency treatment delivered in emergency departments/acute medical units.
- 110 participants across 2 groups, 55 participants will receive NA and 55 will receive ICD.
- Multi-centre (aiming to recruit from roughly 15 UK NHS sites)
- Planned internal progression review after 6 months of recruitment considering the number of centres open and recruitment rates.
- Primary outcome measure is to test whether NA is non-inferior to ICD with respect to the initial length of hospital stay during 30 days from randomisation. If NA is non-inferior to ICD, assess whether NA is superior to ICD with respect to the initial length of hospital stay.

#### Recruitment:

- Potentially eligible participants will be identified by clinical and research teams in the emergency, acute medical and respiratory departments.
- Eligibility assessment will include a chest x-ray to confirm the presence of a pneumothorax.
- If participants are deemed to have the capacity to provide informed consent, a research nurse /clinician discusses the study with the patient and provides the summary and detailed PISs.
- If eligible, has the capacity and is willing to take part written informed consent is obtained either on a paper or electronic Informed Consent Form.
- If eligible, but lacks capacity, auto-enrolled into the study using the deferred consent model based upon HRA guidance on research in emergency settings.
- For those participants who regain capacity within the first 72 hours after randomisation, the information provided about the trial and what has likely happened so far, sign an informed consent form or withdraw.
- For those participants who do not regain capacity within the first 72 hours after randomisation, a consultee will be identified, the study is discussed, sign a consultee declaration form or withdrawn.
- The consent form includes the completion of the study questionnaires as an optional item.

#### Baseline:

- Minimal baseline data recorded before randomisation. Patient-reported outcome measures will be collected within 24 hours of randomisation and after treatment delivery.
- Demographics\*, contact details, consultee details (if necessary)
- Eligibility assessment (pneumothorax details, chest x-ray\*\*, smoking history, underlying lung disease)\*
- Management of previous secondary spontaneous pneumothoraces
- Comorbidities
- National Early Warning Score
- Pain numeric rating scale
- MRC dyspnoea scale
- EQ-5D-5L
- SF-36
- Clinical Frailty Score

\*To be collected before randomisation

\*\*To be collected before randomisation (to assess eligibility) AND after intervention (for intervention evaluation). In the

NA group 1 x-ray will be performed post-intervention, in the ICD group 2 x-rays will be performed 1 after drain insertion and 1 after cessation of bubbling in the water seal (post-intervention).

#### Intervention:

- 55 participants will be treated with needle aspiration
- 55 participants will be treated with intercostal chest drain

Days 1 – 5

- Pain numeric rating scale
- MRC dyspnoea scale
- EQ-5D-5L\*

- SF-36\*

\*To be collected only on day 5

For those discharged before day 5, a participant diary will be given to participants to capture this data.

Day 30

- Chest x-ray

- Length of hospital stay\*

- Pleural interventions

- Clinical assessment

- Hospital re-admittance

- Resolution of SSP

- Pain numeric rating scale

- MRC dyspnoea scale

- EQ-5D-5L

- SF-36

- Clinical Frailty Score

\*Date to death/discharge will try to be captured for participants who remain in the hospital beyond day 30

End of participation in the study.

## **Intervention Type**

Procedure/Surgery

## **Primary outcome(s)**

Length of initial hospital stay (LOHS) from randomisation measured using patient medical notes at Day 30 post-randomisation. Calculated to the nearest hour. Every attempt will be made to collect the date of discharge to calculate LOHS, even if past Day 30, for supporting analyses.

## **Key secondary outcome(s)**

1. Pain measured using a numerical rating scale (NRS) daily for the first 5 days post-randomisation and day 30 post-randomisation
2. Breathlessness measured using the MRC dyspnoea scale daily for the first 5 days post-randomisation and Day 30 post-randomisation
3. Patient-reported health status measured using the EQ-5D-5L and SF-36 questionnaire on Day 5 post-randomisation, and Day 30 post-randomisation
4. Total number of days in hospital including readmissions measured using patient medical notes at Day 30 post-randomisation. Calculated to the nearest hour. Every attempt will be made to collect these dates of discharge to calculate LOHS, even if past Day 30, for supporting analyses
5. Immediate treatment success:
  - 5.1. For NA, success is defined by persistent adequate responses following the aspirations.
  - 5.2. For ICD, success is defined by an adequate response with the removal of a drain within 72 hours of drain insertion
6. Hospital readmission measured using patient medical notes on Day 30 post-randomisation
7. Fitness and frailty measured using the Clinical frailty score Post-intervention and Day 5 post-randomisation
8. Pneumothorax resolution on X-ray measured using patient medical notes on Day 30 post-randomisation
9. Total number of subsequent pleural procedures measured using patient medical notes within first 24 hours and up to 30 days post-randomisation
10. Mortality measured using patient medical notes Day 30 post-randomisation
11. Hospital resource use up to 30 days, including emergency, admitted, critical and outpatient

care measured using patient medical notes on Day 30 post-randomisation

12. Cost effective and utility measured using a health economics resource use questionnaire on Day 30 post-randomisation

**Completion date**

06/06/2025

## Eligibility

**Key inclusion criteria**

Adult patients ( $\geq 18$  years of age) with symptomatic SSP will be potentially eligible if:

1. The pneumothorax is of sufficient size and symptoms for the treating physician to consider intervention with ICD, AND
2. The patient has an SSP, defined as a pneumothorax occurring in a patient:
  - 2.1. With known underlying lung disease OR
  - 2.2.  $\geq 50$  years of age with significant smoking history OR
  - 2.3. With suspected underlying lung disease with radiology confirming structural lung disease

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

Patients will be excluded if there is:

1. Bilateral pneumothorax
2. Traumatic or iatrogenic pneumothorax
3. Clinical concerns of tension pneumothorax
4. Age  $< 18$  years of age
5. Known pregnancy

**Date of first enrolment**

01/06/2023

**Date of final enrolment**

30/04/2025

## Locations

**Countries of recruitment**

United Kingdom

England

Wales

**Study participating centre**

**Southmead Hospital**

Southmead Road  
Westbury-on-trym  
Bristol  
United Kingdom  
BS10 5NB

**Study participating centre**

**St Thomas' Hospital**

Westminster Bridge Road  
London  
United Kingdom  
SE1 7EH

**Study participating centre**

**Derriford Hospital**

Derriford Road  
Derriford  
Plymouth  
United Kingdom  
PL6 8DH

**Study participating centre**

**Royal United Hospitals Bath NHS Foundation Trust**

Combe Park  
Bath  
United Kingdom  
BA1 3NG

**Study participating centre**

**Hull Royal Infirmary**

Anlaby Road

Hull  
United Kingdom  
HU3 2JZ

**Study participating centre**  
**Northern General Hospital**  
Herries Road  
Sheffield  
United Kingdom  
S5 7AU

## Sponsor information

**Organisation**  
North Bristol NHS Trust

**ROR**  
<https://ror.org/036x6gt55>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
Research for Patient Benefit Programme

**Alternative Name(s)**  
NIHR Research for Patient Benefit Programme, Research for Patient Benefit (RfPB), The NIHR Research for Patient Benefit (RfPB), RfPB

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a publicly available repository. All trial data excluding personally identifiable information will be made available indefinitely. Consent from participants will be obtained for data to be stored for the purposes of other ethically approved research in the future and that data will be shared anonymously.

## IPD sharing plan summary

Stored in publicly available repository

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		26/12/2024	17/01/2025	Yes	No
<a href="#">HRA research summary</a>			20/09/2023	No	No